Reduction of elevated IGF-1 levels in coincident amyotrophic lateral sclerosis and acromegaly

Amyotrophic Lateral Sclerosis

Volumn 11, Issue 1-2, 2010, Pages 255-257

  Pereira, Erlick A C ^a   Turner, Martin R ^a   Wass, John A H ^a   Talbot, Kevin ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Epidemiology; Prognostic; Survival

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE; OCTREOTIDE; SOMATOMEDIN C;

ACHILLES REFLEX; ACROMEGALY; ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ARTHRALGIA; CASE REPORT; CLINICAL ASSESSMENT; DENERVATION; DISEASE COURSE; DISEASE DURATION; ECHOCARDIOGRAPHY; ELECTROMYOGRAPHY; FASCICULATION; HEADACHE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERHIDROSIS; IN VITRO STUDY; LEG MOVEMENT; LEG MUSCLE; MALE; MOTONEURON; MUSCLE ATROPHY; MUSCLE WEAKNESS; NERVE CELL GROWTH; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL;

ACROMEGALY; AMYOTROPHIC LATERAL SCLEROSIS; ANTINEOPLASTIC AGENTS; FATAL OUTCOME; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; SOMATOSTATIN;

EID: 77649287654     PISSN: 17482968     EISSN: 1471180X     Source Type: Journal    
DOI: 10.3109/17482960902870985     Document Type: Note

References (20)

1. Turner MR, Parton MJ, Leigh PN. Clinical trials in ALS: an overview. Semin Neurol. 2001;21:167-75.
2. Lewis ME, Vaught JL, Neff NT, Grebow PE, Callison KV, Yu E, et al. The potential of insulin-like growth factor-1 as a therapeutic for the treatment of neuromuscular disorders. Ann N Y Acad Sci. 1993;692:201-8.
3. Wass JA. Growth hormone, insulin-like growth factor-1 and its binding proteins in the follow-up of acromegaly. J Endocrinol. 1997;155 (Suppl 1):S17-9, discussion S21.
4. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf). 1994;41:95-102.
5. Turner MR, Bakker M, Sham P, Shaw CE, Leigh PN, Al-Chalabi A. Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002;3:15-21.
6. Vincent AM, Mobley BC, Hiller A, Feldman EL. IGF-1 prevents glutamate-induced motor neuron programmed cell death. Neurobiol Dis. 2004;16:407-16.
7. Kaspar BK, Llado J, Sherkat N, Rothstein JD, Gage FH. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science. 2003;301:839-42.
8. Dobrowolny G, Giacinti C, Pelosi L, Nicoletti C, Winn N, Barberi L, et al. Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model. J Cell Biol. 2005;168:193-9.
9. Ozdinler PH, Macklis JD. IGF-1 specifically enhances axon outgrowth of corticospinal motor neurons. Nat Neurosci. 2006;9:1371-81.
10. Nagano I, Ilieva H, Shiote M, Murakami T, Yokoyama M, Shoji M, et al. Therapeutic benefit of intrathecal injection of insulin-like growth factor-1 in a mouse model of amyotrophic lateral sclerosis. J Neurol Sci. 2005;235:61-8.
11. Lai EC, Felice KJ, Festoff BW, Gawel MJ, Gelinas DF, Kratz R, et al. Effect of recombinant human insulin-like growth factor-1 on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology. 1997;49:1621-30.
12. Borasio GD, Robberecht W, Leigh PN, Emile J, Guiloff RJ, Jerusalem F, et al. A placebo-controlled trial of insulin-like growth factor-1 in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology. 1998;51:583-6.
13. Sorenson EJ, Windbank AJ, Mandrekar JN, Bamlet WR, Appel SH, Armon C, et al. Subcutaneous IGF-1 is not beneficial in two-year ALS trial. Neurology. 2008;71: 1770-5.
14. Nagano I, Shiote M, Murakami T, Kamada H, Hamakawa Y, Matsubara E, et al. Beneficial effects of intrathecal IGF-1 administration in patients with amyotrophic lateral sclerosis. Neurol Res. 2005;27:768-72.
15. Mitchell JD, Wokke JH, Borasio GD. Recombinant human insulin-like growth factor-1 (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2007(4):CD002064.
16. Hosback S, Hardiman O, Nolan CM, Doyle MA, Gorman G, Lynch C, et al. Circulating insulin-like growth factors and related binding proteins are selectively altered in amyotrophic lateral sclerosis and multiple sclerosis. Growth Horm IGF Res. 2007;17:472-9.
17. Bilic E, Bilic E, Rudan I, Kusec V, Zurak N, Delimar D, et al. Comparison of the growth hormone, IGF-1 and insulin in cerebrospinal fluid and serum between patients with motor neuron disease and healthy controls. Eur J Neurol. 2006;13:1340-5.
18. Pirttila T, Vanhatalo S, Turpeinen U, Riikonen R. Cerebrospinal fluid insulin-like growth factor-1, insulin growth factor binding protein-2 or nitric oxide are not increased in MS or ALS. Acta Neurol Scand. 2004;109:337-41.
19. Traynor BJ, Zhang H, Shefner JM, Schoenfeld D, Cudkowicz ME. Functional outcome measures as clinical trial endpoints in ALS. Neurology. 2004;63:1933-5.
20. Gowers WR. Diseases Of The Nervous System. Philadelphia: P. Blakiston, Son & Co. 1893:483.